Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JLM019 in Advanced Malignancies
NCT07623850Phase 1Recruiting
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JLM019 in solid tumor (advanced stage), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), sponsored by Jecho Biopharmaceuticals Co., Ltd. Primary endpoints: Dose-limiting toxicity at 28 days, Adverse Events at 3 years and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
JLM019
03
Conditions
solid tumor (advanced stage)Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07623850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07623850.